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Background: Patients with gastrointestinal cancers and brain metastases (BM) represent a unique and
heterogeneous population. Our group previously published the Diagnosis-Specific Graded Prognostic
Assessment (DS-GPA) for patients with GI cancers (GI-GPA) (1985–2007, n = 209). The purpose of this
study is to update the GI-GPA based on a larger contemporary database.
Methods: An IRB-approved consortium database analysis was performed using a multi-institutional (18),
multi-national (3) cohort of 792 patients with gastrointestinal (GI) cancers, with newly-diagnosed BM
diagnosed between 1/1/2006 and 12/31/2017. Survival was measured from date of first treatment for
BM. Multiple Cox regression was used to select and weight prognostic factors in proportion to their haz-
ard ratios. These factors were incorporated into the updated GI-GPA.
Results: Median survival (MS) varied widely by primary site and other prognostic factors. Four significant
factors (KPS, age, extracranial metastases and number of BM) were used to formulate the updated GI-
GPA. Overall MS for this cohort remains poor; 8 months. MS by GPA was 3, 7, 11 and 17 months for
GPA 0–1, 1.5–2, 2.5–3.0 and 3.5–4.0, respectively. >30% present in the worst prognostic group (GI-GPA
of 1.0).
40 P.W. Sperduto et al. / Clinical and Translational Radiation Oncology 18 (2019) 39–45Conclusions: Brain metastases are not uncommon in GI cancer patients and MS varies widely among
them. This updated GI-GPA index improves our ability to estimate survival for these patients and will
be useful for therapy selection, end-of-life decision-making and stratification for future clinical trials. A
user-friendly, free, on-line app to calculate the GPA score and estimate survival for an individual patient
is available at brainmetgpa.com.
 2019 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2018, there were an estimated 320,000 invasive gastroin-
testinal (GI) cancers diagnosed, with >160,000 attributable deaths
[1]. An estimated 300,000 patients develop brain metastases (BM)
every year [2]. The cancers most likely to cause BM are lung, breast,
melanoma and renal cell carcinoma. GI cancers cause approxi-
mately 6% of all BM, and because of this relative ‘‘rarity”, few
robust reports have been published [3]. A computerized search of
the medical literature revealed extremely limited published data
regarding the overall survival, or prognostic variables for this
patient population [4,5].
Patients with brain metastases are markedly heterogenous and
it is well-known that outcomes vary widely by diagnosis and
diagnosis-specific prognostic factors [6]. Our group has published
a series of articles defining and updating a prognostic index, the
Graded Prognostic Assessment (GPA) for patients with various pri-
mary diagnoses (lung, breast, melanoma, renal cell and GI cancers)
and BM. Our original GI-GPA was based on 209 GI cancer patients
with BM diagnosed from 1985 to 2005 [7–11]. We recently pub-
lished a study of how prognostic factors have changed in this
patient population in a larger contemporary cohort [12]. The pur-
pose of this study is to update the GI-GPA prognostic index with
these newly identified prognostic factors.
2. Methods
Investigators from a multi-national [3] multi-institutional (18)
consortium created an IRB-approved retrospective database of
845 patients with gastrointestinal cancers and newly-diagnosed
BM between January 1, 2006 and December 31, 2017 using the
Research Electronic Data Capture (REDCap) interactive software.
After exclusions for incomplete data, 792 remained eligible for
analysis. Multiple Cox regression was used to initially select and
weight variables to be included in the new GI-GPA. The initial vari-
ables included in the model were KPS, age, presence of extracranial
metastases, number of brain metastases, gender, stage, primary GI
site, HER2 status and hemoglobin. Multiple imputation using pre-
dictive mean matching [13] was used to impute missing values, so
that the full sample could be used to estimate model parameters.
Both effect magnitude (hazard ratio) and statistical significance
were used to select variables. Weighting options were evaluated
using metrics including the concordance index and R-squared,
using 200 bootstrap replications to estimate out-of-sample perfor-
mance. The final GPA was chosen as a balance of performance met-
rics and simplicity. Kaplan-Meier survival estimates were
calculated for the new GPA categories. Analysis was performed
using R software [14,15].
3. Results
The patient characteristics are shown in Table 1. Noteworthy
observations include: 1) 83% (575/693) presented with stage III
or IV disease; 2) 81% (622/772) had extracranial metastases
(ECM) and 42% (322/772) had liver metastases at the time of diag-
nosis of the BM; 3) In this cohort, the most common primary siteswere: rectum (24%), esophagus (23%), right colon (13%), rectosig-
moid (11%) and GE junction (9%); 4) HER2 was reported in
148/274 (54%) and was present in 59/148 (40%) of patients with
gastric, esophageal and gastro-esophageal cancers. In HER2-
positive patients, 63% received Trastuzumab; 5) the time from pri-
mary diagnosis to brain metastases (TPDBM) was longer in
patients with lung metastases (p < 0.01), females (p < 0.001), col-
orectal cancers (p < 0.001) and early stage (I-II) disease (p < 0.001).3.1. Treatment
Table 2 shows a comparison of survival by treatment for the
current cohort and our prior cohort [6,7]. Notably, treatment pat-
terns have changed from the prior cohort (1989–2007, n = 209)
to the current cohort (2006–2017, n = 792). The use of whole brain
radiation therapy (WBRT) alone has decreased from 45% to 21%
and the use of stereotactic radiosurgery alone has increased from
17% to 39%. Detailed data on systemic therapy before and after
the diagnosis of brain metastases was of interest but was not avail-
able in this retrospective study.3.2. Multivariable model
The multivariable model used to select and weight factors for
the GI-GPA is shown in Table 3. Although 6 factors [Karnofsky Per-
formance Status (KPS), age, extracranial metastases (ECM), number
of BM, hemoglobin and primary GI site] were found to be signifi-
cant, the predictive model was not further enhanced by adding
hemoglobin or primary GI site to the index, and therefore, a simpli-
fied 4-factor model was generated.3.3. Updated GI-GPA
Table 4 shows the definition of the updated GI-GPA and a scor-
ing worksheet to calculate the GI-GPA for any individual patient.
To compare predictive discrimination of the revised and original
GI GPAs, we calculated the concordance probability (c-index) of
two randomly chosen observations. If the patient predicted to live
longer by the GPA actually did live longer, that pair is considered
concordant. Since we have four GPA classes, about 32% of randomly
chosen pairs will have the same predicted survival, thus our theo-
retical maximum achievable c-index is approximately 0.84. The c-
index for the original GI-GPA was 0.610, which improved to 0.633
using the revised GPA.
Fig. 1 shows a Kaplan-Meier curve for survival by GI-GPA group
showing clear separation between adjacent classes (p < 0.001). The
overall MS for this cohort was 8 months. MS by GPA group (0–1.0,
1.5–2.0, 2.5–3.0 and 3.5–4.0) was 3, 7, 11 and 17 months, respec-
tively (p < 0.001). MS (mo) by primary site were: anus (14 mo), left
colon (10 mo), rectosigmoid (10 mo), esophagus (10 mo), small
bowel (8 mo), right colon (7 mo), rectum (7 mo), GE junction
(7 mo), gallbladder (5 mo), pancreas (4 mo), transverse colon
(3 mo) and stomach (2 mo). Table 3 shows a comparison of survival
by treatment and treatment era. Notably, use of WBRT decreased
from 82% in the prior cohort to 34% in the contemporary era.
Table 1
Patient Characteristics, Survival and Time from Primary Diagnosis to Brain Metastases.
Variable Category N (%) Median Survival (IQR) P TPDBM (IQR) P
Overall 792 (100) 8 (3, 18) . 23 (9, 51) .
Original GI-GPA <0.001 0.751
0–1 267 (34) 4 (2, 12) . 24 (7, 48) .
1.5–2 207 (26) 7 (3, 18) . 24 (10, 53) .
2.5–3 187 (24) 12 (6, 21) . 21 (10, 45) .
3.5–4 55 (7) 16 (7, 26) . 23 (11, 61) .
Not Reported 76 (10) 10 (4, 19) . 21 (9, 47) .
KPS <0.001 0.866
<70 113 (14) 3 (1, 8) . 28 (7, 54) .
70 154 (19) 6 (3, 13) . 23 (8, 48) .
80 207 (26) 7 (3, 18) . 24 (10, 53) .
90 187 (24) 12 (6, 21) . 21 (10, 45) .
100 55 (7) 16 (7, 26) . 23 (11, 61) .
Not Reported 76 (10) 10 (4, 19) . 21 (9, 47) .
Number BM <0.001 0.610
1 379 (48) 10 (4, 22) . 23 (10, 47) .
2–3 237 (30) 8 (3, 17) . 26 (10, 56) .
> 3 159 (20) 3 (2, 11) . 23 (8, 49) .
Not Reported 17 (2) 12 (8, 18) . 12 (0, 42) .
Extracranial Mets <0.001 <0.001
Absent 150 (19) 14 (6, 26) . 13 (5, 21) .
Present 622 (79) 7 (3, 15) . 29 (10, 58) .
Not Reported 20 (3) 9 (3, 18) . 14 (8, 41) .
ECM Liver <0.001 0.870
Absent 450 (57) 10 (3, 19) . 22 (10, 52) .
Present 322 (41) 6 (2, 15) . 25 (8, 51) .
Not Reported 20 (3) 9 (3, 18) . 14 (8, 41) .
ECM Bone <0.001 0.041
Absent 604 (76) 9 (3, 18) . 22 (9, 46) .
Present 168 (21) 5 (2, 14) . 30 (9, 60) .
Not Reported 20 (3) 9 (3, 18) . 14 (8, 41) .
ECM Lung 0.004 <0.001
Absent 335 (42) 9 (3, 20) . 13 (5, 28) .
Present 437 (55) 7 (3, 16) . 37 (16, 62) .
Not Reported 20 (3) 9 (3, 18) . 14 (8, 41) .
ECM Other <0.001 0.499
Absent 542 (68) 9 (4, 20) . 24 (10, 51) .
Present 230 (29) 5 (2, 14) . 22 (8, 52) .
Not Reported 20 (3) 9 (3, 18) . 14 (8, 41) .
Age 0.002 0.150
25–52 195 (25) 10 (4, 20) . 26 (12, 46) .
53–61 186 (23) 9 (3, 18) . 24 (9, 57) .
62–68 214 (27) 7 (3, 19) . 19 (7, 40) .
69–92 197 (25) 5 (2, 13) . 25 (9, 59) .
Sex 0.576 <0.001
Male 500 (63) 8 (3, 18) . 20 (8, 46) .
Female 287 (36) 7 (3, 16) . 31 (12, 57) .
Not Reported 5 (1) 9 (8, 12) . 24 (8, 62) .
Race 0.481 0.940
Asian 45 (6) 7 (2, 14) . 23 (9, 55) .
African American 37 (5) 7 (3, 18) . 23 (16, 38) .
White 635 (80) 8 (3, 18) . 23 (9, 52) .
Unknown/Not Reported 75 (9) 7 (3, 18) . 25 (5, 44) .
Ethnicity 0.611 0.956
Not Hispanic or Latino 658 (83) 9 (3, 18) . 23 (9, 51) .
Hispanic or Latino 62 (8) 7 (3, 14) . 24 (9, 56) .
Unknown/Not Reported 72 (9) 5 (2, 12) . 26 (10, 46) .
Primary Tumor Site 0.009 <0.001
Esophagus 181 (23) 10 (3, 21) . 12 (6, 22) .
GE junction 73 (9) 7 (2, 18) . 10 (4, 20) .
Stomach 20 (3) 2 (1, 6) . 14 (7, 23) .
Small Intestine (ie jejunum, d 27 (3) 8 (2, 14) . 17 (2, 53) .
Colon-Right 100 (13) 7 (3, 20) . 31 (12, 57) .
Colon-Transverse 15 (2) 3 (2, 5) . 36 (23, 57) .
Colon-Left 35 (4) 10 (4, 14) . 41 (22, 70) .
Rectosigmoid 90 (11) 10 (4, 20) . 41 (24, 67) .
Rectum 189 (24) 7 (3, 17) . 42 (17, 66) .
Anus 6 (1) 14 (5, 15) . 35 (21, 46) .
Gallbladder 16 (2) 5 (1, 17) . 13 (2, 27) .
(continued on next page)
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Table 1 (continued)
Variable Category N (%) Median Survival (IQR) P TPDBM (IQR) P
Pancreas – adenocarcinoma 30 (4) 4 (3, 14) . 18 (1, 45) .
Not Reported 10 (1) 15 (12, 23) . 66 (29, 87) .
Surgical Resection of Primary Tumor 0.004 <0.001
0 = No 276 (35) 6 (2, 15) . 10 (1, 20) .
1 = Yes 447 (56) 9 (3, 18) . 40 (20, 65) .
Unknown 69 (9) 10 (4, 23) . 20 (3, 34) .
Stage 0.026 <0.001
1 = I 28 (4) 8 (3, 17) . 65 (28, 102) .
2 = II 90 (11) 11 (3, 26) . 47 (23, 70) .
3 = III 245 (31) 9 (3, 18) . 34 (16, 60) .
4 = IV 330 (42) 6 (2, 16) . 12 (2, 28) .
Unknown 99 (13) 9 (3, 18) . 29 (9, 63) .
*HER2 0.066 0.570
0 = Absent 89 (32) 6 (2, 16) . 12 (7, 22) .
1 = Present 59 (22) 13 (6, 23) . 10 (4, 21) .
Not Reported 126 (46) 7 (2, 18) . 12 (5, 22) .
*KRAS 0.111 0.047
0 = Absent 111 (26) 6 (3, 14) . 45 (23, 72) .
1 = Present 130 (30) 10 (4, 19) . 36 (16, 61) .
Not Reported 188 (44) 7 (3, 16) . 36 (15, 59) .
*KRAS Exon 0.369 0.785
1 = G12D 27 (20) 8 (4, 18) . 29 (17, 61) .
2 = G12V 11 (8) 7 (4, 15) . 48 (33, 68) .
3 = G13D 24 (18) 9 (3, 20) . 50 (11, 77) .
9 = Other 32 (24) 14 (6, 26) . 36 (12, 72) .
Unknown 39 (29) 10 (3, 19) . 37 (15, 56) .
*BRAF 0.917 0.938
0 = Absent 130 (30) 9 (4, 17) . 44 (21, 65) .
1 = Present 13 (3) 12 (2, 19) . 49 (17, 68) .
Not Reported 286 (67) 7 (3, 17) . 36 (16, 62) .
EGFR 0.118 0.608
0 = Absent 166 (21) 10 (4, 19) . 33 (14, 57) .
1 = Present 16 (2) 5 (2, 14) . 44 (13, 61) .
Not Reported 610 (77) 7 (3, 18) . 21 (8, 46) .
PIK3CA/P13K 0.398 0.377
0 = Absent 92 (12) 9 (3, 18) . 45 (21, 70) .
1 = Present 15 (2) 14 (6, 21) . 28 (16, 59) .
Not Reported 685 (86) 7 (3, 18) . 21 (8, 46) .
*Hx of Crohns 0.315 0.513
0 = No 353 (82) 7 (3, 17) . 39 (19, 66) .
1 = Yes 2 (0) 6 (1, 11) . 28 (24, 31) .
Unknown 74 (17) 10 (4, 20) . 37 (19, 57) .
*Hx of Ulcerative Col 0.514 0.192
0 = No 350 (82) 7 (3, 16) . 39 (19, 65) .
1 = Yes 5 (1) 4 (4, 20) . 89 (37, 91) .
Unknown 74 (17) 10 (4, 20) . 37 (19, 57) .
Microsatellite status 0.380 0.803
0 = Unstable 8 (1) 14 (6, 25) . 24 (16, 56) .
1 = Stable 97 (12) 8 (3, 19) . 30 (9, 58) .
Unknown 687 (87) 8 (3, 17) . 23 (9, 49) .
Hemoglobin <0.001 0.473
[5, 11) 121 (15) 3 (1, 6) . 27 (9, 58) .
[11, 12.5) 123 (16) 6 (2, 18) . 26 (12, 53) .
[12.5, 14.1) 122 (15) 7 (3, 19) . 23 (10, 47) .
[14.1, 164] 124 (16) 11 (5, 19) . 21 (7, 51) .
Not Reported 302 (38) 12 (4, 21) . 21 (8, 47) .
Neutrophil-to-lymphoc 0.569 0.498
[0.07, 3.30) 76 (10) 6 (3, 16) . 19 (11, 35) .
[3.30, 6.86) 80 (10) 4 (3, 12) . 21 (5, 43) .
[6.86, 12.50) 76 (10) 5 (2, 12) . 23 (10, 56) .
[12.50, 112] 78 (10) 4 (1, 18) . 22 (8, 61) .
Not Reported 482 (61) 10 (4, 19) . 24 (10, 52) .
LDH 0.170 0.939
[1, 196) 36 (5) 7 (3, 18) . 22 (10, 51) .
[196, 347) 33 (4) 4 (3, 9) . 25 (11, 60) .
[347, 517) 33 (4) 7 (3, 18) . 17 (13, 40) .
[517, 4369] 33 (4) 5 (2, 14) . 25 (5, 60) .
Not Reported 657 (83) 9 (3, 18) . 24 (9, 49) .
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Table 1 (continued)
Variable Category N (%) Median Survival (IQR) P TPDBM (IQR) P
BMI 0.396 0.044
[11.8, 22.1) 82 (10) 4 (2, 17) . 23 (15, 54) .
[22.1, 26.0) 86 (11) 6 (3, 16) . 17 (6, 38) .
[26.0, 30.1) 87 (11) 7 (3, 22) . 17 (6, 44) .
[30.1, 80.8] 86 (11) 9 (3, 14) . 22 (10, 41) .
Not Reported 451 (57) 10 (3, 18) . 27 (10, 56) .
* Only applies to a subset of primary tumor types. PT: Primary Tumor. Median survival is in months from start of BM treatment (Kaplan-Meier estimate). IQR = Interquartile
Range. TPDBM = time from primary diagnosis to start of BM treatment, in months. Variables were measured at time of BM diagnosis. P-values are from log-rank (survival) or
Kruskal-Wallis (TPDBM) test of equivalence among categories, excluding unknown/not reported.
Table 2
Survival by Treatment and Treatment Era.
Overall WBRT SRS WBRT+SRS S+SRS S+WBRT S+WBRT+SRS
Historical Cohort
N (%) 209 95 (45%) 35 (17%) 35 (17%) 2 (1%) 34 (16%) 8 (4%)
Mean GPA 2.0 1.8 2.4 2.1 3.5 2.4 1.8
Median Survival 5 3 7 7 9 10 8
Risk of Death (HR) 1.0 0.72 0.69 2.30 0.33 0.39
95% CI 0.40, 1.28 0.39, 1.22 0.43, 12.4 0.19, 0.56 0.17, 0.90
P-value 0.26 0.21 0.33 <0.01 0.03
Current Study
N (%) 792 166 (21%) 309 (39%) 31 (4%) 121 (15%) 67 (8%) 5 (1%)
Mean GPA 2.0 1.7 2.1 2.0 2.1 2.1 1.6
Median Survival 8 3 6 12 11 14 4
Risk of Death (HR) 1.0 0.87 0.67 0.45 0.49 0.70
95% CI 0.69, 1.10 0.43, 1.04 0.33, 0.60 0.35, 0.68 0.24, 2.07
P-value 0.25 0.08 <0.01 <0.01 0.52
Abbreviations: WBRT: whole brain radiation therapy; SRS: stereotactic radiosurgery; S: surgery (craniotomy).
Hazard ratio (HR), 95% CI, and p (each treatment vs. WBRT alone within each cohort) adjusted for GPA. Median survival is unadjusted, in months. 11 patients in the current
study did not have an initial treatment reported. 70 had surgery alone and 12 had fractionated partial brain radiation alone.
Table 3
Hazard Ratio Results of Multi-Variable Analyses of Significant Prognostic Factors.
Parameter Categories N (%) HR (95% CI)
KPS 90–100 242 (31) 1.0 (Ref)
80 207 (26) 1.6 (1.3, 2.0)
<80 267 (34) 2.1 (1.6, 2.7)
Age <60 340 (43) 1.0 (Ref)
60 452 (57) 1.3 (1.1, 1.6)
ECM Absent 150 (19) 1.0 (Ref)
Present 622 (79) 1.8 (1.4, 2.2)
# BM 1 379 (48) 1.0 (Ref)
2–3 237 (30) 1.4 (1.1, 1.7)
>3 159 (20) 1.9 (1.6, 2.4)
Note: Two other factors (hemoglobin and primary GI site) were significant but
incorporating those factors did not improve the model so were excluded for
simplicity.
Table 4
Definition of the Updated Prognostic Index, the Graded Prognostic Assessment for Patients w
Estimate Survival.
Prognostic Factor GI-GPA Scoring Criteria
0 0.5 1
KPS <80 n/a 8
Age 60 <60 n
ECM Present Absent n
# of BM >3 2–3 1
Median Survival by GI-GPA Group: 0–1.0, 1.5–2.0, 2.5–3.0, 3.5–4.0 was 3, 9, 12 and
extracranial metastases; # of BM, number of brain metastases; n/a, not applicable.
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Brain metastases in patients with GI cancers are not uncom-
mon. Survival varies widely within this cohort based on the prog-
nostic factors presented in this report. In contrast to the prior
cohort in which only KPS status was prognostic, this study identi-
fies multiple new prognostic factors and incorporates them into an
updated user-friendly prognostic index, the Graded Prognostic
Assessment for gastrointestinal cancer patients with brain metas-
tases (GI-GPA). Patients with GI cancers and brain metastases also
represent a unique patient population because they have a worse
prognosis than any other primary diagnosis except small cell lung
cancer. Our findings are consistent with prior reports [3–6] that
performance status and number of metastases are important prog-
nostic factors but further refine our ability to predict survival for
these patients with the identification of additional factors.
Other smaller studies [3–5] have reported that brain metastases
in GI cancer patients occur late in the course of disease.ith Gastrointestinal Cancers and Brain Metastases (GI-GPA) and Scoring Worksheet to
Patient Score
.0 1.5 2.0
0 n/a 90–100 –
/a n/a n/a –
/a n/a n/a –
n/a n/a –
Sum Total –
17 months, respectively. Abbreviations: KPS, Karnofsky Performance Score; ECM,
Months from start of BM treatment
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Fig. 1. Kaplan-Meier Curve for Survival by GI-GPA Group.
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cer to BM (TPDBM) is 23 months [12] which is longer than that of
lung cancer (16 mo) and renal cell carcinoma (19 mo) but shorter
than the TPDBM for melanoma (32 mo) and breast cancer (38 mo).
However, MS of a GI cancer patient after the diagnosis of BM (8mo)
is far worse than any other diagnoses listed above. (lung non-
adenocarcinoma 9 mo, lung adenocarcinoma 15 mo, breast 14
mo, melanoma 10 mo, renal cell 12 mo) [6–11]. Certainly the pro-
clivity of GI cancers to not just extracranial sites (80%) but partic-
ularly the liver (42%) is a likely explanation for the worse
prognosis.
Given the fact that 83% of patients in this study presented with
stage III or IV disease, physicians should be aware that such
patients are at high risk for developing BM, and although a role
for routine screening has not been established, any CNS symptoms
deserve scrutiny.
Her2-positivity may become a prognostic factor in the future as
more and more patients are being tested in the current era. In this
study, HER2-positivity showed a trend (p = 0.066) toward
improved survival in patients with gastric, esophageal and gastroe-
sophageal cancers.
For patients with poor prognosis (GI-GPA  1.0), discussion of
supportive care or hospice, as established by the QUARTZ trial for
NSCLC BM patients [16] might be reasonable. Physicians should
have frank conversations with their patients and their families
regarding expected survival, quality-of-life, and end-of-life care.
4.1. Limitations
Limitations of this study include the retrospective nature of the
database and the selection bias inherent in all retrospective stud-
ies. Accordingly, one cannot conclude one treatment is better than
another (Table 2) based on these data. Secondly, although the sam-
ple size is large, the molecular profile was not frequently reported.
Thirdly, detailed data on use of chemotherapy and immunotherapy
before and after the diagnosis of brain metastases are lacking in
these data. Fourthly, we grouped all primary GI sites in this analy-
sis but each primary GI site may behave differently as suggested by
the HER2 data discussed above.5. Conclusions
Contrary to conventional wisdom, brain metastases are not
uncommon in patients with GI cancers. Furthermore, median sur-vival within this cohort varies widely (from 3 to 17 months) based
on multiple recently identified prognostic factors. Compared to
other diagnoses, patients with GI cancers and BM are a unique pop-
ulation associated with poor prognosis overall. The updated GI-
GPA prognostic index improves our ability to estimate survival
for these patients and will be useful for end-of-life decision-
making and stratification for future clinical trials. In order to sim-
plify calculation of individual patient’s GPA, a free, user-friendly
app, which can be easily downloaded to a smart phone or clinic
computer is available at brainmetgpa.com.
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